GoAI
Get started
Xikang Cloud Hospital Holdings Inc. logo

Xikang Cloud Hospital Holdings Inc.

9686.HK

HKSEHealthcareMedical - Healthcare Information Services

Open in GoAI

Latest quote

HK$0.85

HK$0.00 · 0.00%

Aug 20, 3:56 PM HKT

9686.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Xikang Cloud Hospital Holdings Inc. specializes in constructing customized digital healthcare platforms designed for urban settings. Its business operations are structured into four main categories: Cloud Hospital Platform Services, Internet Medical Services, Health Management Services, and Smart Healthcare Products. The Cloud Hospital Platform Services unit provides advanced technological solutions to local governmental bodies, medical institutions, and insurance providers. Through its Internet Medical Services, the company offers a range of options including virtual hospital consultations, remote medical support, intelligent family physician initiatives, and online home care assistance. The Health Management Services division delivers comprehensive wellness oversight and specific chronic condition management programs. Lastly, the Smart Healthcare Products segment markets innovative health-related devices to a broad customer base, encompassing municipal authorities, primary care facilities, businesses, and individual consumers. The company was founded on May 12, 2011, and its headquarters are situated in Shanghai, China.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
CN
CEO
Wenhong Zong
Listed since
Sep 28, 2023
Employees
763

Market position

52-week range

Current HK$0.85

Open
HK$0.85
Previous close
HK$0.85
Volume
210K
7.89× average
Average volume
26.6K
Average daily volume
Market cap
715.6M HKD
Beta
0.26
Market reference 1
50-day average
HK$0.8988
-5.43% below average
200-day average
HK$0.9116
-6.76% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
653.56M CNY
P/E (TTM)
-15.78×
P/B (TTM)
1.96×
P/S (TTM)
1.32×
EV / EBITDA
-28.02×
Earnings yield
-5.72%
Free cash flow yield
2.19%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
27.35%
Operating margin
-8.70%
Net margin
-8.39%
Return on equity
-12.42%
Return on assets
-3.41%
Return on invested capital
-4.71%

Financial health

Debt / equity
1.66×
Current ratio
1.17×
Altman Z-score
-2.26
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends39%7%-25%-56%Gross margin, FY2021: 27.71%Gross margin, FY2022: 24.50%Gross margin, FY2023: 30.61%Gross margin, FY2024: 29.41%Gross margin, FY2025: 27.35%Operating margin, FY2021: -41.28%Operating margin, FY2022: -28.44%Operating margin, FY2023: -20.39%Operating margin, FY2024: -8.76%Operating margin, FY2025: -8.70%Net margin, FY2021: -48.27%Net margin, FY2022: -35.20%Net margin, FY2023: -28.76%Net margin, FY2024: -16.56%Net margin, FY2025: -8.39%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.71%. Gross margin FY2022 24.50%. Gross margin FY2023 30.61%. Gross margin FY2024 29.41%. Gross margin FY2025 27.35%. Operating margin FY2021 -41.28%. Operating margin FY2022 -28.44%. Operating margin FY2023 -20.39%. Operating margin FY2024 -8.76%. Operating margin FY2025 -8.70%. Net margin FY2021 -48.27%. Net margin FY2022 -35.20%. Net margin FY2023 -28.76%. Net margin FY2024 -16.56%. Net margin FY2025 -8.39%.

Income trends

Revenue

464.14M CNY-7.45%

Operating income

−40.39M CNY+8.11%

Net income

−38.93M CNY+53.13%
Income trends across reported periods785.81M CNY392.23M CNY−1.35M CNY−394.93M CNYRevenue, FY2021: 614.3M CNYRevenue, FY2022: 687.42M CNYRevenue, FY2023: 537.72M CNYRevenue, FY2024: 501.5M CNYRevenue, FY2025: 464.14M CNYOperating income, FY2021: −253.6M CNYOperating income, FY2022: −195.48M CNYOperating income, FY2023: −109.65M CNYOperating income, FY2024: −43.95M CNYOperating income, FY2025: −40.39M CNYNet income, FY2021: −296.54M CNYNet income, FY2022: −241.97M CNYNet income, FY2023: −154.65M CNYNet income, FY2024: −83.05M CNYNet income, FY2025: −38.93M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 614.3M CNY. Revenue FY2022 687.42M CNY. Revenue FY2023 537.72M CNY. Revenue FY2024 501.5M CNY. Revenue FY2025 464.14M CNY. Operating income FY2021 −253.6M CNY. Operating income FY2022 −195.48M CNY. Operating income FY2023 −109.65M CNY. Operating income FY2024 −43.95M CNY. Operating income FY2025 −40.39M CNY. Net income FY2021 −296.54M CNY. Net income FY2022 −241.97M CNY. Net income FY2023 −154.65M CNY. Net income FY2024 −83.05M CNY. Net income FY2025 −38.93M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue464.14M CNY501.5M CNY537.72M CNY687.42M CNY614.3M CNY
Cost of goods sold337.18M CNY354M CNY373.11M CNY518.97M CNY444.07M CNY
Gross profit126.96M CNY147.5M CNY164.61M CNY168.45M CNY170.23M CNY
Research and development32.69M CNY42.01M CNY55.58M CNY78.96M CNY86.42M CNY
Selling, general, and administrative134.66M CNY149.44M CNY214.66M CNY291.83M CNY54.53M CNY
Operating expenses167.35M CNY191.45M CNY274.26M CNY363.93M CNY423.83M CNY
Interest income16.42M CNY20.9M CNY5.22M CNY4.81M CNY1.21M CNY
Interest expense21.98M CNY27.02M CNY38.28M CNY42.88M CNY36.31M CNY
Depreciation and amortization8.99M CNY8.31M CNY33.7M CNY34.02M CNY41.83M CNY
Operating income−40.39M CNY−43.95M CNY−109.65M CNY−195.48M CNY−253.6M CNY
Net income−38.93M CNY−83.05M CNY−154.65M CNY−241.97M CNY−296.54M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.046
FY2025
Latest fiscal-year revenue
464.14M CNY
FY2025 · -7.45% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.01-0.15-0.29-0.42FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend709.74M620.43M531.12M441.81MFY21FY22FY23FY24FY25

9686.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.66

-3.20%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.42

-5.06%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.10

-5.99%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.45

-2.88%

Continue in GoAI

Research 9686.HK

research.disclaimer